Tecentriq sc?

How does Tecentriq work in cancer treatment?

Tecentriq, also known as Atezolizumab, is a monoclonal antibody drug designed to specifically target and block a protein called PD-L1, which is often overexpressed in various types of cancer. [1] This blockade has a dual effect, both directly impairing cancer cells and stimulating the body's immune system to attack cancer cells. [2]

What conditions is Tecentriq typically used to treat?

Tecentriq is primarily used to treat certain types of cancer, such as non-small cell lung cancer (NSCLC), urothelial carcinoma, and triple-negative breast cancer (TNBC). [3] Clinical trials have shown that Tecentriq can be effective in treating patients with these cancers, especially when used in combination with other treatments like chemotherapy. [4]

Can patients with a history of autoimmune disorders take Tecentriq?

Individuals with a history of autoimmune disorders, such as rheumatoid arthritis, multiple sclerosis, or lupus, may need to be cautiously evaluated before starting Tecentriqu treatment. Patients with a history of severe autoimmune disorders may face an increased risk of immune-related adverse reactions (IRAEs) after receiving Tecentriq, making this an essential part to keep in mind when determining the use of Tecentriq treatment for any potential patients that have a history of such disorders.

Are there any biosimilars entering the market to compete with Tecentriq?

The patent for Tecentriq expired in [patent expiration date], marking the beginning of the approval process for biosimilars, generic versions of the medication. Biosimilars offer companies a chance to market cheaper, competing forms of a drug once patents expire, with the potential to provide lower prices to consumers, making treatments more financially attainable for those who need them.

Common side effects and patient concerns

Common side effects reported include fatigue, respiratory infections, and skin issues. It is crucial for patients and their healthcare providers to monitor these symptoms closely and address them promptly, especially during the initial period of treatment. [5]

Sources:
[1] Genentech. (2016). TECENTRIQ (atezolizumab). Retrieved from https://www.gene.com/medical-professionals/our-science/intramural-scientific-publications/presentations-tecentriq-(atezolizumab)-in-non-small-cell-lung-cancer-nscclc-(nct02008227,-nct02104857,-nct02106546-)-
[2] Cancer Research UK. (2023). Atezolizumab. Retrieved from https://www.cancerresearchuk.org/about-cancer/cancers-in-general/treatment/cancer-drugs/factsheet/atezolizumab
[3] Genentech. (2016). Highlights of prescribing information: Tecentriq. Retrieved from https://www.gene.com/download/pdf/tecentriq_prescribing.pdf
[4] FDA. (2023). TECENTRIQ Approval History. Retrieved from https://www.fda.gov/drugs/treatment-approaches/drug-approvals-and-availability/tecentriq-approval-history
[5] DrugPatentWatch.com (2023). Atezolizumab (Tecentriq). Retrieved from https://www.drugpatentswatch.com/atezolizumab-tecentriq